Favorable Press Coverage Somewhat Unlikely to Affect Johnson & Johnson (JNJ) Share Price

Headlines about Johnson & Johnson (NYSE:JNJ) have been trending positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.4578828019409 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern’s rankings:

Shares of Johnson & Johnson (NYSE JNJ) traded down $0.94 during mid-day trading on Monday, hitting $140.12. 4,665,500 shares of the stock were exchanged, compared to its average volume of 5,897,919. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35. The company has a market capitalization of $376,440.00, a price-to-earnings ratio of 24.33, a PEG ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.68 earnings per share. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.

Several brokerages have issued reports on JNJ. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Citigroup lifted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Argus lifted their target price on shares of Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $145.47.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/25/favorable-press-coverage-somewhat-unlikely-to-affect-johnson-johnson-jnj-share-price.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit